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activation testDear Editor,
Etanercept is a dimeric human recombinant protein composed
by tumour necrosis factor receptor p75 and Fc portion of human
IgG1. It irreversibly and competitively binds to membrane and cir-
culant TNF-a, preventing its interaction with membrane receptors
on immune effector cells.
Etanercept is considered one of the ﬁrst-line therapies for
various inﬂammatory and autoimmune diseases including rheuma-
toid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile
idiopathic arthritis.1 However, the development of local and sys-
temic hypersensitivity reactions to etanercept contraindicates its
use in sensitized patients.
Adverse reactions induced by biologics are very diverse, and its
true incidence is unknown. In the 2012 review of BIOBADASER
(Spanish Registry for Adverse Events of Biological Therapy in Rheu-
matic Diseases), 16 361 adverse events were registered in a popula-
tion of 6754 patients treatedwithmonoclonal antibodies, mainly to
anti-TNF agents. Among these reactions, 2.788 were considered se-
vere and 215 fatal (1.3% of all reactions). The most frequent causes
of adverse events were infectious diseases (31%) and malignant
neoplasms (19.5%), whereas immune reactions only represented
0.5%.2 Immune reactions to etanercept reported in literature
include injection site reactions (ISRs) and immediate systemic hy-
persensitivity reactions such as pruritus, urticaria, angioedema
and anaphylaxis, among others.3e5
In controlled trials in rheumatologic indications, around 37% of
patients treated with etanercept developed ISRs3 and in some of
them they were even the most common adverse event reported.4
Additionally, non-neutralizing antibodies against etanercept have
been observed in 18.3% of psoriatic patients treated with the
drug, although this ﬁnding had no apparent effect on safety or efﬁ-
cacy of treatment.5 It is thought that ISRs are due to late hypersen-
sitivity reactions (or T cell-mediated type IV immune reactions),
and that they could preclude the subsequent administration of
the drug.6 Zeltser et al.7 demonstrated that the perivascular inﬁl-
trate of etanercept ISRs consisted primarily of mature activated
cytotoxic T lymphocytes. These reactions take several hours
(24e48 h). This differs to an IgE-mediated mast cell and basophil
activation (immediate type I) allergic response, which is associated
with a wheal-and-ﬂare skin reaction and, potentially, systemic
anaphylaxis.Peer review under responsibility of Japanese Society of Allergology.
http://dx.doi.org/10.1016/j.alit.2016.09.002
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mediated reactions have been applied to non-IgE-mediated ones,
with seemingly similar outcomes, but involved mechanisms are
unknown. Rapid desensitization is a procedure that makes it
possible to continue the administration of monoclonal therapies af-
ter development of hypersensitivity reactions in cases in which an
adequate alternative does not exist,8 and a wide variety of desensi-
tization protocols have been reported.8,9 Speciﬁcally, desensitiza-
tion protocols to etanercept have been described, and they are
performed to date in 6 steps repeated in 3 days.9
We hereby describe a successful desensitization 8-step protocol
in one day carried out in 2 patients with psoriatic arthritis present-
ing adverse reactions to etanercept.
Patients and methods
Patient 1: A 52-years-old woman diagnosed with psoriatic
arthritis that three hours after injection presented erythema, pruri-
tus andsevere oedema (15e20cm indiameter) at the site of injection
after ﬁfth weekly dose of etanercept (Fig. 1A), which lasted for 12 h.
Patient 2: A 37-years-old woman diagnosed with psoriatic
arthritis. Two hours after administration of the second dose of eta-
nercept, she presented with pruritus, erythema and oedema (10 cm
in diameter) at the site of injection (Fig. 1C) followed by generalized
urticaria without angioedema, that lasted for 4 days and required
intravenous treatment with 45.5 mg of dexchlorpheniramine and
40 mg of methylprednisolone.
Due to the failure of previous treatment with methotrexate,
hydroxychloroquine and prednisone, both patients were referred
to the allergy department to consider the possibilities to success-
fully perform a desensitization procedure to etanercept, a drug
that had good responses in the past in both patients.
Basophil activation tests (BAT) and skin tests with etanercept
were performed in both cases. The latter consisted of prick tests us-
ing the undiluted drug (25 mg/mL) and of intradermal tests using
serial dilutions (1:10 and 1:100). Prick tests were examined at
20min and intradermal tests at 15min and 24, 48 and 72 h; a result
was considered positive when a wheal 3 mm greater of negative
control was obtained.
Results
The results of skin tests with etanercept were negatives in both
patients. The same tests were done in ﬁve healthy controls and skinvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. A, Typical ISR induced by etanercept in patient 1; B, The same patient after etanercept desensitization. C, Typical ISR induced by etanercept in patient 2; D, The same patient
after etanercept desensitization. EeG, Results of basophil activation test for patient 1 showing etanercept hypersensitivity. The basophils were identiﬁed as SSClow/CD203chigh. E, As
negative control, background basophil activation with stimulation buffer only (0.5%). F, As positive control, basophil activation with anti-speciﬁc IgE antibodies (79%). G, The
percentage of activated (CD63þ) basophils stimulated by etanercept was 75%.
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were positive in both patients; the percentages of activated baso-
phils by etanercept were 75% in patient 1 (Fig.1EeG) and 58% in pa-
tient 2 (data not shown). The BAT with etanercept results were
negative in patients who were treated with etanercept but without
hypersensitivity reactions to etanercept. We did not observe a
reduction of etanercept induced CD63 expression level in our pa-
tients at the end of the etanercept desensitization protocol.
Patients received premedication with dexamethasone (20 mg
orally) and dexchlorpheniramine (5 mg intramuscular) 1 h beforeTable 1
Subcutaneous desensitization protocol with etanercept.
Dose Time (min) Dose
administered
(mg)
Dilution Volume
administered
(mL)
1 0 0.005 1:10000 (0.005 mg/mL) 1
2 15 0.05 1:1000 (0.05 mg/mL) 1
3 15 0.5 1:100 (0.5 mg/mL) 1
4 15 1 1:10 (5 mg/mL) 0.2
5 15 3 1:10 (5 mg/mL) 0.6
6 15 8 1:1 (50 mg/mL) 0.16
7 15 16 1:1 (50 mg/mL) 0.32
8 15 22 1:1 (50 mg/mL) 0.44
Total time ¼ 105 min (1 h 45 min)
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to etanercept in two patients with positive basophil activation test, Allergothe beginning of desensitization protocol. This consisted of subcu-
taneous administration of 8 doses every 15 min until reaching a
cumulative therapeutic dose of 50 mg (Table 1). There were no
adverse reactions during desensitization. Fifteen days after desen-
sitization, each patient received a full dose of etanercept divided
between the two arms (to avoid high local deposits of the drug)
and the full dose in one arm 15 days after. During the last 8
months, patients have been able to continue with etanercept,
with minor local erythema resolving within 1e2 h (Fig. 1B and
D, respectively).Conclusions
The recent development of the quantiﬁcation of basophil activa-
tion by ﬂow cytometry represents a new opportunity for the diag-
nosis of drug allergies. The BAT has proven to be a reliable and valid
candidate marker to monitor subcutaneous venom immuno-
therapy.10 However, we did not observe a reduction of etanercept
induced CD63 expression level in our patients at the end of the eta-
nercept desensitization protocol.
We present a new safe and effective 8-step protocol of rapid
subcutaneous desensitization to etanercept in one day, being a
valid alternative for patients with adverse hypersensitivity reac-
tions to this drug. Rapid desensitization is a temporary phenome-
non that appears to inhibit mast cell activation and mast cell-cutaneous desensitization for treatment of hypersensitivity reactions
logy International (2016), http://dx.doi.org/10.1016/j.alit.2016.09.002
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spectives to continue the administration of biologic therapies after
hypersensitivity reactions in cases inwhich an appropriate alterna-
tive does not exist. This fact represents a major advantage to pa-
tients because it shortens the time elapsed to tolerance and to
the administration of the optimal treatment for their diseases.
However, studies involving a larger number of patients will be
needed to evaluate the safety and efﬁcacy of this rapid desensitiza-
tion approach in patients with ISR to etanercept.Conﬂict of interest
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